Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO). ASH - Usmani, S Z; Nahi, H; Mateos, M V (2016)
Abstract 1149